Effects of Exendin(9-39) on Gastroduodenal Motility
Status:
Completed
Trial end date:
2000-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study in humans is to define the effects of the endogenous hormone GLP-1
on gastroduodenal motility and on endocrine pancreatic secretion by using the specific GLP-1
receptor antagonist exendin(9-39). To elucidate possible cholinergic pathways, we combined
exendin(9-39) with the muscarinergic antagonist atropine.
Phase:
Phase 1
Details
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Collaborators:
German Research Foundation Philipps University Marburg Medical Center